LSE (The London School of Economics and Political Science). 2010. Policies and incentives for promoting innovation in antibiotic research. http://www2.lse.ac.uk/newsAndMedia/news/archives/2009/09/antibiotics.aspx (accessed March 14, 2010).

Matheny, J., M. Mair, and B. Smith. 2008. Cost/success projections for U.S. biodefense counter-measure development. Nature Biotechnology 26(9):981–983.

Melese, T., S. M. Lin, J. L. Chang, and N. H. Cohen. 2009. Open innovation networks between academia and industry: An imperative for breakthrough therapies. Nature Medicine 15:502–507.

NBSB (National Biodefense Science Board). 2010a. Where are the Countermeasures? Protecting America’s Health From CBRN Threats. http://www.hhs.gov/aspr/barda/documents/phemceimplplan_041607final.pdf (accessed May 17, 2010).

NBSB. 2010b. Optimizing industrial involvement in medical countermeasure development. http://www.hhs.gov/aspr/omsph/nbsb/nbsbrpt-2010.pdf (accessed March 2, 2010).

PhRMA. 2010. R&D investment by U.S. biopharmaceutical companies remains strong despite ongoing economic challenges. http://www.phrma.org/news/news/rd_investment_us_biopharmaceutical_companies_remains_strong_despite_ongoing_economic_chall (accessed March 30, 2010)

Wolf, M. C., A. N. Freiberg, T. Zhang, A. Akyol-Ataman, A. Grock, et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proceedings of the National Academy of Sciences 107(7):3157–3162.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement